Intellia Therapeutics, Inc. - Common Stock (NTLA)

Intellia Therapeutics is a biotechnology company focused on developing innovative gene-editing therapies to treat serious genetic diseases

The company leverages its proprietary CRISPR/Cas9 technology platform to create precise and effective treatments that have the potential to address the root causes of diseases. By advancing its research and clinical programs, Intellia aims to pioneer new therapeutic approaches that could significantly improve patient outcomes and transform the landscape of genetic medicine.